HC Wainwright Estimates Omeros’ Q1 Earnings (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) – Stock analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Omeros in a research report issued to clients and investors on Wednesday, April 1st. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of ($0.40) for the quarter, up from their prior estimate of ($0.59). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.54) EPS, FY2027 earnings at ($0.08) EPS, FY2028 earnings at $2.05 EPS, FY2029 earnings at $4.06 EPS and FY2030 earnings at $5.23 EPS.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $3.69.

OMER has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Tuesday, January 27th. Finally, Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Omeros Price Performance

Shares of Omeros stock opened at $10.90 on Friday. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65. The company has a market capitalization of $784.80 million, a PE ratio of -21.80 and a beta of 2.53. The business has a 50-day moving average of $11.36 and a 200-day moving average of $9.83.

Insiders Place Their Bets

In other Omeros news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC raised its position in shares of Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after acquiring an additional 79,263 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Omeros during the fourth quarter worth $159,000. Invesco Ltd. boosted its holdings in Omeros by 26.8% in the fourth quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock worth $2,658,000 after purchasing an additional 32,707 shares during the period. Virtus Investment Advisers LLC acquired a new position in Omeros in the fourth quarter worth $450,000. Finally, Wellington Management Group LLP increased its stake in Omeros by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock valued at $3,480,000 after purchasing an additional 8,170 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Key Headlines Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros says it has reached a profitability milestone as part of a strategic shift toward commercialization and partnerships, which management says should improve cash flow and de-risk the business. Omeros Reaches Profitability Milestone Amid Strategic Shift
• Positive Sentiment: HC Wainwright raised near-term EPS estimates for multiple 2026 quarters and lifted FY2026/FY2027 forecasts, while keeping a Buy rating and a $40 price target — a bullish analyst stance that supports higher share valuations. HC Wainwright raises estimates and reiterates Buy, $40 PT
• Positive Sentiment: Q4 results were stronger than expected (company-reported EPS beat and a licensing/deal with Novo Nordisk cited as boosting Q4), providing immediate revenue/earnings proof points that likely pushed the stock higher. Omeros rises as Novo deal boosts Q4 earnings
• Positive Sentiment: Unusually large call-option purchases were reported, signaling bullish positioning by traders and adding short-term upside pressure. Traders Purchase Large Volume of Call Options on Omeros
• Neutral Sentiment: Several analyst and market-commentary pieces outline the bull case ahead of Q1 commercial updates and provide earnings-call detail — useful for context but not immediate catalysts on their own. Omeros: Making The Bull Case On Q4 Earnings
• Neutral Sentiment: Earnings call transcript and summaries are available for deeper detail on guidance and commercialization plans; these will matter when management discusses Q1 commercial progress. Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed several longer-term EPS estimates (FY2028–FY2030), lowering some multi-year upside expectations — a signal that while near-term outlook improved, longer-term model risk remains. HC Wainwright trims long-term EPS forecasts

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.